Nalaganje...
Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells
BACKGROUND: Combined endocrine therapy with a cyclin-dependent kinase (CDK) 4/6 inhibitor has been indicated to improve not only progression-free survival, but also overall survival in patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer. However, resistance to this com...
Shranjeno v:
| izdano v: | Breast Cancer |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Springer Japan
2020
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7796879/ https://ncbi.nlm.nih.gov/pubmed/32860163 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12282-020-01150-8 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|